Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Appointed director

CNS Pharmaceuticals, Inc. (CNSP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
10/12/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
10/12/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
10/12/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
10/12/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
10/12/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
08/23/2023 4 Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Bought 27,000 shares @ $1.2658, valued at $34.2k
08/18/2023 8-K Quarterly results
08/16/2023 4 Climaco John M (CEO) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Bought 2,750 shares @ $1.798, valued at $4.9k
08/15/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF CNS PHARMACEUTICALS, INC."
08/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/14/2023 8-K Quarterly results
Docs: "CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
08/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/01/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
05/15/2023 8-K Quarterly results
Docs: "CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 4 Cockroft Bettina M. (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Granted 8,300 options to buy @ $1.67, valued at $13.9k
05/09/2023 3 Cockroft Bettina M. (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc.
05/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors"
05/01/2023 4 Climaco John M (CEO) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Exercised 1,250 restricted stock units @ $0
05/01/2023 4 Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Exercised 521 restricted stock units @ $0
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/31/2023 4 Climaco John M (CEO) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Granted 16,467 restricted stock units @ $0
03/31/2023 4 Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Granted 6,067 restricted stock units @ $0
03/31/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 10% stake in CNS Pharmaceuticals, Inc.
01/04/2023 4 Charles Faith L. (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Granted 3,500 options to buy @ $2.4, valued at $8.4k
01/04/2023 3 Charles Faith L. (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy